## Dirk Van Gestel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9512640/publications.pdf

Version: 2024-02-01

84 papers

1,051 citations

471509 17 h-index 30 g-index

87 all docs

87 docs citations

87 times ranked

1585 citing authors

#	Article	IF	CITATIONS
1	Intensityâ€Modulated Radiation Therapy for Head and Neck Carcinoma. Oncologist, 2007, 12, 555-564.	3.7	106
2	Soft tissue sarcoma of the extremities: pending questions on surgery and radiotherapy. Radiation Oncology, 2016, 11, 136.	2.7	74
3	Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. Frontiers in Oncology, 2019, 9, 86.	2.8	71
4	Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?. Current Opinion in Oncology, 2019, 31, 54-64.	2.4	66
5	Multi-institutional comparison of volumetric modulated arc therapy vs. intensity-modulated radiation therapy for head-and-neck cancer: a planning study. Radiation Oncology, 2013, 8, 26.	2.7	62
6	DNA methylation-based biomarkers in serum of patients with breast cancer. Mutation Research - Reviews in Mutation Research, 2012, 751, 304-325.	5.5	60
7	Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity. Radiotherapy and Oncology, 2013, 109, 323-329.	0.6	58
8	RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison. Radiation Oncology, 2013, 8, 37.	2.7	45
9	Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research. Frontiers in Oncology, 2021, 11, 784947.	2.8	37
10	Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments. Frontiers in Oncology, 2021, 11, 799993.	2.8	28
11	Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience. British Journal of Radiology, 2011, 84, 367-374.	2.2	24
12	68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy. World Journal of Urology, 2019, 37, 1535-1542.	2.2	23
13	The Potential of Helical Tomotherapy in the Treatment of Head and Neck Cancer. Oncologist, 2013, 18, 697-706.	3.7	21
14	Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093609.	3.2	21
15	A dosimetric comparison of two-phase adaptive intensity-modulated radiotherapy for locally advanced nasopharyngeal cancer. Journal of Radiation Research, 2015, 56, 529-538.	1.6	20
16	Retrospective evaluation of the safety of low-level laser therapy/photobiomodulation in patients with head/neck cancer. Supportive Care in Cancer, 2020, 28, 3015-3022.	2.2	20
17	Follow-Up of Head and Neck Cancer Survivors: Tipping the Balance of Intensity. Frontiers in Oncology, 2020, 10, 688.	2.8	20
18	The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers, 2019, 11, 1093.	3.7	18

#	Article	IF	Citations
19	Clinical outcome and toxicity after simultaneous integrated boost IMRT in head and neck squamous cell cancer patients. Oral Oncology, 2019, 98, 132-140.	1.5	18
20	Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2. Cancer Medicine, 2020, 9, 1069-1078.	2.8	18
21	Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis. Oncologist, 2016, 21, 59-71.	3.7	16
22	Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial. BMC Cancer, 2021, 21, 899.	2.6	16
23	Evaluation of the optimal combinations of modulation factor and pitch for Helical TomoTherapy plans made with TomoEdge using Pareto optimal fronts. Radiation Oncology, 2015, 10, 191.	2.7	14
24	Evolution of selfâ€perceived swallowing function, tongue strength and swallowâ€related quality of life during radiotherapy in head and neck cancer patients. Head and Neck, 2019, 41, 2197-2207.	2.0	14
25	Metaâ€Analysis on Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma. Oncologist, 2021, 26, e130-e141.	3.7	12
26	Oligometastatic Disease Detection with 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact. Cancers, 2021, 13, 4982.	3.7	12
27	3D Monte Carlo dosimetry of intraoperative electron radiation therapy (IOERT). Physica Medica, 2019, 57, 207-214.	0.7	11
28	Feasibility of tongue strength measurements during (chemo)radiotherapy in head and neck cancer patients. Supportive Care in Cancer, 2017, 25, 3417-3423.	2.2	10
29	Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial. BMC Cancer, 2021, 21, 514.	2.6	10
30	Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110458.	3.2	9
31	Fast Helical Tomotherapy in a head and neck cancer planning study: is time priceless?. Radiation Oncology, 2015, 10, 261.	2.7	8
32	Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2020, 10, 282.	2.8	8
33	AÂfeasibility study on adaptive 18F-FDG-PET-guided radiotherapy for recurrent and second primary head and neck cancer in the previously irradiated territory. Strahlentherapie Und Onkologie, 2018, 194, 727-736.	2.0	7
34	OC-0625 Immuno-radiotherapy in solid tumors: preliminary results of the randomized phase 2 CHEERS trial. Radiotherapy and Oncology, 2021, 161, S490-S491.	0.6	7
35	The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein. BMC Cancer, 2014, 14, 594.	2.6	6
36	Impact of the COVID-19 Pandemic on Patients and Staff in Radiation Oncology Departments in Belgium: A National Survey. Frontiers in Oncology, 2021, 11, 654086.	2.8	6

#	Article	IF	CITATIONS
37	Preoperative and postoperative radiotherapy (RT) for non-small cell lung cancer: still an open question. Translational Lung Cancer Research, 2021, 10, 1950-1959.	2.8	6
38	Brachytherapy in Belgium in 2018. A national survey of the brachytherapy study group of the Belgian SocieTy for Radiotherapy and Oncology (BeSTRO). Radiotherapy and Oncology, 2020, 150, 245-252.	0.6	5
39	Assessment of cough in head and neck cancer patients at risk for dysphagia—An overview. Cancer Reports, 2021, 4, e1395.	1.4	5
40	Prophylactic gastrostomy in locally advanced head and neck cancer: results of a national survey among radiation oncologists. BMC Cancer, 2021, 21, 656.	2.6	5
41	Technologic Advances in External Beam Radiotherapy for Head and Neck Cancer. Oncology & Hematology Review, 2013, 09, 109.	0.2	5
42	The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease. Cancers, 2022, 14, 2046.	3.7	5
43	Unusual presentation of a hepatocellular carcinoma as a potential late side effect of radiotherapy in a patient treated for Wilms tumor in childhood. World Journal of Surgical Oncology, 2018, 16, 48.	1.9	4
44	Monte Carlo dose calculations of shielding disks with different material combinations in intraoperative electron radiation therapy (IOERT). Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 128-134.	1.4	4
45	Unintended dose to the lower axilla in adjuvant radiotherapy for breast cancer: Differences between tangential beam and VMAT. Radiotherapy and Oncology, 2021, 164, 282-288.	0.6	4
46	Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 53-58.	2.4	4
47	Helical Tomotherapy in Head and Neck Cancer: A European Singleâ€Center Experience. Oncologist, 2015, 20, 279-290.	3.7	3
48	Dose-response in choroidal melanoma. Radiotherapy and Oncology, 2018, 127, 374-378.	0.6	3
49	Split-VMAT technique to control the deep inspiration breath hold time for breast cancer radiotherapy. Radiation Oncology, 2021, 16, 77.	2.7	3
50	Successful treatment of synchronous chemoresistant pulmonary metastasis from pleomorphic rhabdomyosarcoma with stereotaxic body radiation therapy: A case report and a review of the literature Cancer Treatment and Research Communications, 2021, 26, 100282.	1.7	3
51	Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry. Advances in Radiation Oncology, 2021, 7, 100767.	1.2	2
52	Ossifying Fibromyxoid Tumor with Spinal Cord Compression and Epiduritis. Journal of the Belgian Society of Radiology, 2019, 103, 18.	0.3	2
53	Integration of the M6 Cyberknife in the Moderato Monte Carlo platform and prediction of beam parameters using machine learning. Physica Medica, 2020, 70, 123-132.	0.7	2
54	Recent advances in radiosensitivity determinants in melanoma. Current Opinion in Oncology, 2022, 34, 131-138.	2.4	2

#	Article	IF	Citations
55	Qualitative evaluation of the role of RTTs IGRT specialists and their influence on treatment delivery. Technical Innovations and Patient Support in Radiation Oncology, 2022, 22, 9-15.	1.9	2
56	The outcome of the first 100 nasopharyngeal cancer patients in thailand treated by helical tomotherapy. Radiology and Oncology, 2017, 51, 351-356.	1.7	1
57	In Regard to Perrier etÂal. International Journal of Radiation Oncology Biology Physics, 2017, 97, 204-205.	0.8	1
58	OC-0634 Lymphocyte Sparing Radiation Therapy for stage III NSCLC: a dosimetric study. Radiotherapy and Oncology, 2021, 161, S498-S500.	0.6	1
59	Heterotopic ossification and severe COVID-19 infection. QJM - Monthly Journal of the Association of Physicians, 2022, 115, 201-203.	0.5	1
60	Barriers in education and professional development of Belgian medical imaging technologists and nurses working in radiotherapy: A qualitative study. Radiography, 2022, 28, 620-627.	2.1	1
61	PO-0605: Factors associated with late dysphagia and xerostomia in (chemo)radiation for head and neck cancer. Radiotherapy and Oncology, 2017, 123, S315-S316.	0.6	0
62	Results of helical tomotherapy on mycosis fungoides lesions. European Journal of Cancer, 2018, 101, S31.	2.8	0
63	Mycosis fungoides, insights in the latest therapy options and the possibility of a promising use of helical tomotherapy. European Journal of Cancer, 2018, 101, S31.	2.8	0
64	EP-1171: Toxicity and outcome for simultaneous integrated boost radiotherapy in head and neck cancer patients. Radiotherapy and Oncology, 2018, 127, S655-S656.	0.6	0
65	EP-2321: Evolution of OLIG2 expression during radio(chemo)therapy has a prognostic value in glioblastoma. Radiotherapy and Oncology, 2018, 127, S1280-S1281.	0.6	0
66	PO-1067 High expression of CCND2 in glioblastoma is associated with an increased risk of early mortality Radiotherapy and Oncology, 2019, 133, S593-S594.	0.6	0
67	Evaluation and Validation of an Image-Guided Traffic Light Protocol for Head and Neck Cancer Patients Undergoing Radiotherapy. Journal of Medical Imaging and Radiation Sciences, 2019, 50, S2-S3.	0.3	0
68	Prophylactic cranial irradiation (PCI) or magnetic resonance imaging (MRI) monitoring in limited small cell lung cancer: is it a question?. Precision Cancer Medicine, 0, 2, 10-10.	1.8	0
69	PO-125: Induction chemotherapy in Locally Advanced Nasopharyngeal carcinoma is of benefit?. Radiotherapy and Oncology, 2019, 141, S52-S53.	0.6	0
70	84TiP Neo-CheckRay: Radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer: A randomized phase II trial. Annals of Oncology, 2020, 31, S1451.	1.2	0
71	Editorial: Quality Assessment Across Disciplines in Head and Neck Cancer Treatment. Frontiers in Oncology, 2021, 11, 636622.	2.8	0
72	Evaluation of the XVI dual registration tool for image-guided radiotherapy in prostate cancer. Technical Innovations and Patient Support in Radiation Oncology, 2021, 18, 22-28.	1.9	0

#	Article	IF	CITATIONS
73	Radiotherapy: An Alternative to Surgery. , 0, , .		О
74	PO-1384 Salvage radiotherapy for locally recurrent prostate cancer after high-intensity focused ultrasound. Radiotherapy and Oncology, 2021, 161, S1134-S1135.	0.6	0
75	PH-0218 Functionality-optimised radiotherapy for lung cancer patients using SPECT/CT. Radiotherapy and Oncology, 2021, 161, S151-S152.	0.6	O
76	OC-0315 Qualitative evaluation of the role of RTTs IGRT specialists and their influence on treatment quality. Radiotherapy and Oncology, 2021, 161, S225-S226.	0.6	0
77	PO-1860 Physical vs. biological based VMAT optimization for prostate cancer radiotherapy. Radiotherapy and Oncology, 2021, 161, S1584-S1585.	0.6	0
78	PH-0375 Lymphocyte-sparing in pelvic radiotherapy for prostate cancer: an in-silico planning study. Radiotherapy and Oncology, 2021, 161, S273-S274.	0.6	0
79	Abstract 5722: Retention of the radiosensitizing effect of gemcitabine and its main metabolite dFdU under reduced oxygen conditions is not influenced by HIF-1 functionality., 2012,,.		O
80	Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 17588359211045860.	3.2	0
81	PD-0072: Evaluation of intra thoracic anatomical changes based on the lung traffic light protocol. Radiotherapy and Oncology, 2020, 152, S31-S32.	0.6	0
82	PD-0420: Induction by mFOLFIRINOX followed by SIBSBRT for the neoadjuvant treatment of pancreatic cancer Radiotherapy and Oncology, 2020, 152, S228.	0.6	0
83	PO-1352: Prediction of electron beam parameters of a Monte Carlo model using machine learning. Radiotherapy and Oncology, 2020, 152, S716-S717.	0.6	0
84	PD-0177: Interfraction heart motion during Deep Inspiration Breath Hold (DIBH) radiotherapy measured by CBCT Radiotherapy and Oncology, 2020, 152, S86-S87.	0.6	0